prostaglandin EP4 receptor antagonist (Eli Lilly)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameprostaglandin EP4 receptor antagonist (Eli Lilly)
Drug Alias NameEP4-R antagonist (Eli Lilly)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP4 receptor antagonists
TargetsProstanoid EP4 receptor
Therapy Area/IndicationsOsteoarthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsOsteoarthritis

Other Information

ATC CodeN/A
Related LinksN/A